纳曲酮结构式
|
常用名 | 纳曲酮 | 英文名 | naltrexone |
|---|---|---|---|---|
| CAS号 | 16590-41-3 | 分子量 | 341.40 | |
| 密度 | 1.5±0.1 g/cm3 | 沸点 | 558.1±50.0 °C at 760 mmHg | |
| 分子式 | C20H23NO4 | 熔点 | 168-170ºC | |
| MSDS | N/A | 闪点 | 291.4±30.1 °C | |
| 符号 |
GHS02, GHS06, GHS08 |
信号词 | Danger |
纳曲酮用途Naltrexone 是 Opioid receptor 的拮抗剂。Naltrexone 在体内抑制细胞增殖。Naltrexone 通过干扰细胞信号和改变免疫系统来抑制肿瘤生长。 |
| 中文名 | 纳曲酮 |
|---|---|
| 英文名 | naltrexone |
| 中文别名 | 17-(环丙甲基)-4,5-环氧-3,14-二羟基吗啡烷-6-酮 | 纳屈酮 |
| 英文别名 | 更多 |
| 描述 | Naltrexone 是 Opioid receptor 的拮抗剂。Naltrexone 在体内抑制细胞增殖。Naltrexone 通过干扰细胞信号和改变免疫系统来抑制肿瘤生长。 |
|---|---|
| 相关类别 | |
| 参考文献 |
[7]. Naltrexone |
| 密度 | 1.5±0.1 g/cm3 |
|---|---|
| 沸点 | 558.1±50.0 °C at 760 mmHg |
| 熔点 | 168-170ºC |
| 分子式 | C20H23NO4 |
| 分子量 | 341.40 |
| 闪点 | 291.4±30.1 °C |
| 精确质量 | 341.162720 |
| PSA | 70.00000 |
| LogP | 1.80 |
| 蒸汽压 | 0.0±1.6 mmHg at 25°C |
| 折射率 | 1.709 |
| 储存条件 | 库房通风低温干燥,与氧化剂,食品分开储运 |
| 符号 |
GHS02, GHS06, GHS08 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H225-H301 + H311 + H331-H370 |
| 警示性声明 | P210-P260-P280-P301 + P310-P311 |
| 危害码 (欧洲) | F,T |
| 风险声明 (欧洲) | 11-23/24/25-39/23/24/25 |
| 安全声明 (欧洲) | 16-36/37-45 |
| 危险品运输编码 | UN1230 - class 3 - PG 2 - Methanol, solution |
| 纳曲酮上游产品 9 | |
|---|---|
| 纳曲酮下游产品 6 | |
|
Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
J. Pharmacol. Exp. Ther. 350(1) , 69-78, (2014) The opioid and cannabinoid systems play a crucial role in multiple physiological processes in the central nervous system and in the periphery. Selective opioid as well as cannabinoid (CB) receptor ago... |
|
|
Desensitization of functional µ-opioid receptors increases agonist off-rate.
Mol. Pharmacol. 86(1) , 52-61, (2014) Desensitization of µ-opioid receptors (MORs) develops over 5-15 minutes after the application of some, but not all, opioid agonists and lasts for tens of minutes after agonist removal. The decrease in... |
|
|
Treatment of alcohol dependence: recent progress and reduction of consumption.
Minerva Med. 105(6) , 447-66, (2014) Alcohol dependence (AD) is a major public health problem. Currently, three drugs for the treatment of AD have been approved by both the European Medicines Agency (EMA) and the Food and Drug Administra... |
| Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- |
| Trexonil |
| NeMexin |
| (1S,5R,13R,17S)-4-(Cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-on |
| Depotrex |
| ReVia |
| en1939 |
| Naltrel |
| en1639 |
| Naltrexone |
| Vivitrol |
| (5α)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one |
| Antaxone |
| trexan |
| (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-one |
| (1S,5R,13R,17S)-4-(cyclopropylméthyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadéca-7(18),8,10-trién-14-one |
| celupan |
| En 1639A |
| Um-792 |
| (5a)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one |
| Nalorex |
| Depade |